Table 3 |
||||
|
Clinical characteristics of patients in the GC-S and GC-I groups according to the use of glucocorticoids |
||||
|
Use of GCs |
No use of GCs |
|||
|
|
||||
|
GC-S (n = 24) |
GC-I (n = 13) |
GC-S (n = 44) |
GC-I (n = 15) |
|
|
|
||||
|
Age at delivery in years, mean (SD) |
34.1 (3.1) |
34.1 (3.6) |
31.6 (3.9) |
31.2 (3.0) |
|
Disease duration in years, median (range) |
4.6 (0.2-28.6) |
6.8 (1.0-22.7) |
5.3 (0.1-28.5) |
2.4 (0.2-28.4) |
|
Gestational age at delivery in weeks, mean (SD) |
39.0 (1.9)A |
37.4 (2.2) |
39.8 (1.3) |
39.9 (1.3) |
|
Anti-CCP positive, n (%) |
16 (66.7) |
8 (61.5) |
24 (54.5) |
6 (40%) |
|
Rheumatoid factor (IgM) positive, n (%) |
17 (70.8) |
10 (76.9) |
31 (70.5) |
9 (60.0) |
|
Presence of erosions, n (%) |
22 (91.7) |
13 (100) |
28 (63.6) |
8 (53.3) |
|
Dosage of prednisone (pregnancy; mg/day), median (range) |
6.25 (2.5-15) |
8.75 (5-20) |
- |
- |
|
Dosage of prednisone (postpartum; mg/day), median (range) |
8.75 (2.5-15) |
10.0 (5-15) |
- |
- |
|
Number of DMARDs before conception, median (range) |
2 (0-4) |
2 (1-5) |
2 (0-4) |
2 (0-3) |
|
Moderate/good response during pregnancy, n (%) |
5/11 (45.5) |
4/9 (44.4) |
8/16 (50) |
5/11 (45.5) |
|
Very early flare, N/Ntotal (%) |
5/21 (23.8) |
3/13 (23.1) |
10/41 (24.4) |
5/13 (38.5) |
|
Early flare, N/Ntotal (%) |
4/21 (19.0) |
2/12 (16.7) |
12/40 (30.0) |
3/13 (23.1) |
|
Late flare, N/Ntotal (%) |
4/19 (21.1) |
4/13 (30.8) |
15/37 (40.5) |
4/12 (33.3) |
|
Breastfeeding (6 weeks postpartum), n (%) |
8 (33.3) |
1 (7.7) |
20 (45.5) |
8 (53.3) |
|
Use of NSAIDs at 6 months postpartum,a N/Ntotal (%) |
7/22 (31.8)b |
10/13 (76.9) |
13/40 (32.5) |
6/13 (46.2) |
|
Use of MTX at 6 months postpartum,a N/Ntotal (%) |
11/22 (50.0) |
9/13 (69.2) |
10/40 (25.0) |
5/13 (38.5) |
|
Use of sulfasalazine at 6 months postpartum,a N/Ntotal (%) |
6/22 (27.3) |
2/13 (15.4) |
17/40 (42.5) |
6/13 (46.2) |
|
Use of anti-TNF-α at 6 months postpartum,a N/Ntotal (%) |
3/22 (13.6) |
3/13 (23.1) |
2/40 (5.0) |
0/13 (0) |
|
|
||||
|
Data concerning response during pregnancy, very early flare, early flare, and late flare were present in 47, 88, 86, and 81 patients, respectively. aAvailable in 88 patients. bP < 0.05 compared with GC-I, use of GC. Anti-CCP, anti-cyclic citrullinated protein; TNF-α, tumor necrosis factor-alpha. |
||||
|
Quax et al. Arthritis Research & Therapy 2012 14:R183 doi:10.1186/ar4014 |
||||
